{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T04:10:40Z","timestamp":1778299840392,"version":"3.51.4"},"reference-count":18,"publisher":"Japan Endocrine Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1507\/endocrj.ej25-0539","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T22:08:25Z","timestamp":1769033305000},"page":"587-596","source":"Crossref","is-referenced-by-count":0,"title":["Lenvatinib in radioiodine-refractory differentiated thyroid cancer: a real-world institutional analysis"],"prefix":"10.1507","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6768-4107","authenticated-orcid":false,"given":"Sueyoshi","family":"Moritani","sequence":"first","affiliation":[{"name":"Center for Otolaryngology, Head and Neck Thyroid Surgery, Omi Medical Center, Shiga 525-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Takenobu","sequence":"additional","affiliation":[{"name":"Center for Otolaryngology, Head and Neck Thyroid Surgery, Omi Medical Center, Shiga 525-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Yasunaga","sequence":"additional","affiliation":[{"name":"Center for Otolaryngology, Head and Neck Thyroid Surgery, Omi Medical Center, Shiga 525-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taihei","family":"Fujii","sequence":"additional","affiliation":[{"name":"Center for Otolaryngology, Head and Neck Thyroid Surgery, Omi Medical Center, Shiga 525-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mako","family":"Moritani","sequence":"additional","affiliation":[{"name":"Center for Otolaryngology, Head and Neck Thyroid Surgery, Omi Medical Center, Shiga 525-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Bando","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Omi Medical Center, Shiga 525-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Oda","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Omi Medical Center, Shiga 525-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Omi Medical Center, Shiga 525-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroya","family":"Kitano","sequence":"additional","affiliation":[{"name":"Center for Otolaryngology, Head and Neck Thyroid Surgery, Omi Medical Center, Shiga 525-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, et al. (2015) Lenvatinib <i>versus<\/i> placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372: 621\u2013630.","DOI":"10.1056\/NEJMoa1406470"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Kiyota N, Schlumberger M, Muro K, Ando Y, Takahashi S, et al. (2015) Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci 106: 1714\u20131721.","DOI":"10.1111\/cas.12826"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Onaga R, Enokida T, Tanaka N, Hoshi Y, Kishida T, et al. (2025) Long-term clinical outcomes of patients with differentiated thyroid cancer treated with lenvatinib: results from real-world practice in Japan. Thyroid 35: 781\u2013788.","DOI":"10.1089\/thy.2025.0040"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Takahashi S, Tahara M, Ito K, Tori M, Kiyota N, et al. (2020) Safety and effectiveness of lenvatinib in 594 patients with unresectable thyroid cancer in an all-case post-marketing observational study in Japan. Adv Ther 37: 3850\u20133862.","DOI":"10.1007\/s12325-020-01433-8"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Cabanillas ME, Ryder M, Jimenez C (2019) Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr Rev 40: 1573\u20131604.","DOI":"10.1210\/er.2019-00007"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Sugitani I, Kiyota N, Ito Y, Onoda N, Hiromasa T, et al. (2025) The 2024 revised clinical guidelines on the management of thyroid tumors by the Japan Association of Endocrine Surgery. Endocr J 72: 545\u2013635.","DOI":"10.1507\/endocrj.EJ24-0644"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7 Ringel MD, Sosa JA, Baloch Z, Bischoff L, Bloom G, et al. (2025) 2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer. Thyroid 35: 841\u2013985.","DOI":"10.1177\/10507256251363120"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Matsuyama C, Enokida T, Ueda Y, Suzuki S, Fujisawa T, et al. (2023) Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study. Front Oncol 13: 1139659.","DOI":"10.3389\/fonc.2023.1139659"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9 Tahara M, Takami H, Ito Y, Okamoto T, Sugitani I, et al. (2024) A prospective cohort study exploring the effect of lenvatinib planned drug holidays in treatment of differentiated thyroid cancer. Thyroid 34: 566\u2013574.","DOI":"10.1089\/thy.2023.0553"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Iwamoto H, Suzuki H, Shimose S, Niizeki T, Nakano M, et al. (2020) Weekends-off lenvatinib for unresectable hepatocellular carcinoma improves therapeutic response and tolerability toward adverse events. Cancers (Basel) 12: 1010.","DOI":"10.3390\/cancers12041010"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Robinson B, Schlumberger M, Wirth LJ, Dutcus CE, Song J, et al. (2016) Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer. J Clin Endocrinol Metab 101: 4103\u20134109.","DOI":"10.1210\/jc.2015-3989"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Tahara M, Kiyota N, Hoff AO, Badiu C, Owonikoko TK, et al. (2021) Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer 147: 51\u201357.","DOI":"10.1016\/j.ejca.2020.12.032"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Sabra MM, Sherman EJ, Tuttle RM (2017) Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma. Cancer 123: 2955\u20132964.","DOI":"10.1002\/cncr.30690"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Tamai T, Hayato S, Hojo S, Suzuki T, Okusaka T, et al. (2017) Dose finding of lenvatinib in subjects with advanced hepatocellular carcinoma based on population pharmacokinetic and exposure-response analyses. J Clin Pharmacol 57: 1138\u20131147.","DOI":"10.1002\/jcph.917"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Hayato S, Shumaker R, Ferry J, Binder T, Dutcus CE, et al. (2018) Exposure-response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer. Cancer Chemother Pharmacol 82: 971\u2013978.","DOI":"10.1007\/s00280-018-3687-4"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Tahara M, Brose MS, Wirth LJ, Suzuki T, Miyagishi H, et al. (2019) Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer 106: 61\u201368.","DOI":"10.1016\/j.ejca.2018.10.002"},{"key":"17","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1186\/s12885-021-08622-w","volume":"21","author":"C Masaki","year":"2021","unstructured":"17 Masaki C, Sugino K, Kobayashi S, Hosoi Y, Ono R, et al. (2021) Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients. BMC Cancer 21: 894.","journal-title":"BMC Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/1471-2407","issn-type":"print"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Fukuda N, Toda K, Wang X, Ohmoto A, Hayashi N, et al. (2021) Prognostic significance of 8 weeks\u2019 relative dose intensity of lenvatinib in treatment of radioiodine-refractory differentiated thyroid cancer patients. Endocr J 68: 639\u2013647.","DOI":"10.1507\/endocrj.EJ20-0754"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/73\/5\/73_EJ25-0539\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T03:23:00Z","timestamp":1778296980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/73\/5\/73_EJ25-0539\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej25-0539","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"EJ25-0539"}}